

DxTernity Inks Updated Thermo Fisher Licensing Deal Eyes global delivery of Modular Immune Profile (MIP) Assay for Autoimmune Disease

LOS ANGELES, CA – November 8, 2019 – [DxTernity Diagnostics Inc.](#) has announced the signing of a multi-year licensing and supply agreement with Thermo Fisher Scientific. Under the terms of the agreement, DxTernity is granted the ability to pursue regulatory clearance for its Modular Immune Profile (MIP) test, also known as the Autoimmune Profile (AIP) test, in conjunction with the ABI 3500Dx Genetic Analyzer.

DxTernity's MIP is a 51-plex gene expression assay that uses modular genomics to monitor activity of 12 immune system related biological pathways as well as several key therapeutic biomarkers. MIP is currently being used by multiple pharmaceutical companies for enrollment and monitoring of systemic lupus erythematosus (SLE) patients in phase II clinical trials, and a recent clinical study showed that the type 1 interferon activity level from MIP is prognostic for risk of an SLE patient developing lupus nephritis ($p=0.0008$).

"This agreement paves the way for DxTernity pursuing companion and complementary diagnostic claims across multiple regulatory diseases. Today, our primary focus is on SLE, however as demonstrated in a 1000-participant multiple sclerosis (MS) study last year, MIP has broad applicability for therapy response and disease activity monitoring. Importantly, MIP is designed for both doctor's office and home monitoring when used in conjunction with the DxCollect® fingerstick collection kit. MIP plays a central role in DxTernity's efforts to bring precision medicine to autoimmune disease", according to Bob Terbrueggen, Founder and CEO of DxTernity.

About DxTernity

DxTernity is a molecular information and diagnostics company bringing precision medicine to autoimmune treatment with from-home RNA monitoring. DxTernity also provides services and technologies to partner organizations, including population-scale genomic studies. For more information, please visit [DxTernity.com](#) or follow us on [LinkedIn](#), [Twitter](#), [Facebook](#).

DxTernity's fingerstick collection device (DxCOLLECT® Microcollection Device) is For Investigational Use Only. The performance characteristics of this product have not been established.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than \$24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit [www.thermofisher.com](#).

Media Contact:

Melanie Anderson
Pitch Public Relations
Melanie@PitchPublicRelations.com
480.225.7148

<https://swkhold.investorroom.com/2019-11-08-DxTernity-Inks-Updated-Thermo-Fisher-Licensing-Deal>